导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.97% | 4058/4773 |
| 近一周 | -2.47% | 3914/5465 |
| 近一月 | 4.82% | 97/5421 |
| 近一季 | 3.30% | 474/5231 |
| 近半年 | -7.55% | 3371/4920 |
| 近一年 | -2.11% | 3022/4394 |
| 近两年 | 27.70% | 2388/2954 |
| 近三年 | 27.70% | 1181/2253 |
| 成立以来 | 93.18% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-12.68% 4538/4961 |
-11.66% 4318/5312 |
- - |
- - |
| 2025 | 21.49% 2033/4813 |
-3.53% 3059/3635 |
11.09% 221/4076 |
-2.47% 3982/4524 |
16.24% 30/4813 |
| 2024 | 43.12% 4/3463 |
2.39% 785/2808 |
6.17% 178/3014 |
37.73% 70/3129 |
-4.41% 2464/3463 |
| 2023 | -5.19% 720/2656 |
-0.53% 1802/2280 |
5.76% 58/2385 |
4.43% 151/2515 |
-13.70% 2468/2655 |
| 2022 | -4.82% 110/2207 |
-8.62% 287/1919 |
0.14% 1581/2016 |
-6.93% 109/2113 |
11.76% 140/2208 |
| 2021 | -21.73% 1178/1822 |
-4.27% 853/1255 |
-7.36% 1282/1330 |
-10.63% 1232/1466 |
-1.25% 1341/1822 |
| 2020 | 11.34% 827/1250 |
-17.10% 998/1028 |
4.16% 916/1067 |
18.98% 74/1164 |
8.37% 675/1184 |
| 2019 | 40.76% 246/1092 |
26.47% 407/754 |
5.74% 15/804 |
0.82% 458/850 |
4.40% 802/918 |
| 2018 | -23.87% 302/834 |
- - |
- - |
- - |
-14.76% 594/691 |
| 2017 | 42.36% 22/714 |
- - |
- - |
- - |
- - |
| 2016 | -6.26% 196/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 方正富邦中证保险A VS. 长安沪深300非周期A(740101) |